Progression-Free Survival Represents Clinical Benefit, But How Much? – ODAC
Executive Summary
While the Oncologic Drugs Advisory Committee generally endorses the idea that progression-free survival can support full approval of first-line therapies in metastatic breast cancer, the panel left FDA with the challenge of qualifying how PFS represents clinical benefit and determining the measure's meaningfulness for regulatory purposes
You may also be interested in...
Genentech May Not Get A Chance To Appeal FDA's Decision To Withdraw Avastin's Breast Cancer Approval
Genentech has been clear that it intends to appeal FDA's determination that the breast cancer indication for Avastin should be revoked, but the agency may not let the appeal go forward.
Genentech May Not Get A Chance To Appeal FDA's Decision To Withdraw Avastin's Breast Cancer Approval
Genentech has been clear that it intends to appeal FDA's determination that the breast cancer indication for Avastin should be revoked, but the agency may not let the appeal go forward.
Provenge Poised For Broad Insurance Coverage, Despite Grumbles On Price
After a strong endorsement in the National Comprehensive Cancer Network guidelines, Dendreon's first-of-its-kind prostate cancer vaccine Provenge appears well positioned for broad insurance coverage and take-up with physicians